ArticleCureus2025
Evaluating Drug-Eluting Balloons Versus Stenting for Provisional Bifurcation Lesions: Short-Term Outcomes and Future Directions.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Revascularization with drug-coated balloons alone in complex coronary artery disease: a systematic review.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Yiqi Huoxue Tongluo decoction combined with conventional medicine therapy: effects on restenosis rates and clinical efficacy in patients with coronary heart disease undergoing percutaneous coronary intervention.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background This prospective cohort study aimed to evaluate the short-term clinical outcomes of drug-eluting balloons (DEBs) versus stenting in provisional bifurcation lesions, focusing on procedural success, safety, and major adverse cardiac events (MACE). The study specifically assessed key adverse outcomes, including restenosis, target lesion revascularization (TLR), myocardial infarction (MI), stent thrombosis, and mortality. Bifurcation lesions present significant challenges in interventional cardiology due to their complex anatomy, which contributes to a higher risk of restenosis, side-branch occlusion, and thrombotic events. This study compared the efficacy, safety, and procedural complexity of DEBs and stenting. Methodology Fifty patients with bifurcation lesions were enrolled and divided into two equal groups: 25 (50%) treated with DEBs and 25 (50%) treated with provisional stenting. The primary outcome measure was the incidence of MACE, including TLR, MI, stent thrombosis, and death. The study was conducted over one year, with follow-up assessments at one- and three months post-intervention. After the intervention, all patients were put on dual antiplatelet therapy (DAPT) comprising aspirin, clopidogrel, and high-intensity statins. Additionally, other medications were prescribed based on patient-specific needs. Results The DEB group exhibited an overall MACE rate of 2 (8%) compared with 3 (12%) in the stenting group (p = 0.58). Restenosis occurred in 1 (4%) of the DEB group and in 2 (8%) of the stenting group, whereas TLR was required in 1 (4%) and 2 (8%) of the patients, respectively. The incidence of MI was low in both groups 1 (4%), with no reported cases of stent thrombosis or death. No significant differences were observed between the groups in any of the clinical outcome measures (p > 0.05). The DEB group achieved treatment success without necessitating side-branch stenting or additional kissing balloon inflation, whereas the stenting group demonstrated comparable success, but increased procedural complexity. Conclusion DEBs and stenting showed comparable short-term efficacy and safety for provisional bifurcation lesions, offering the potential advantage of procedural simplicity. This study supports the viability of DEBs as an effective treatment option for selected bifurcation lesions, avoiding the additional complexities associated with stenting. However, larger studies with extended follow-up are necessary to validate these findings and inform clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.